Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
ELEDON PHARMACEUTICALS INC
ELDN | US
3.03
USD0.06
2.02%
ELDN | US
About ELEDON PHARMACEUTICALS INC
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
21/10/2024
Close
3.03
Open
2.90
High
3.09
Low
2.90
Eledon Pharmaceuticals Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart an anti-CD40L antibody with high affinity for CD40 Ligand a biological target with therapeutic potential. It has a collaboration agreement with eGenesis Inc. The company was formerly known as Novus Therapeutics Inc. and changed its name to Eledon Pharmaceuticals Inc. in January 2021. Eledon Pharmaceuticals Inc. is headquartered in Irvine California.
View LessELDN | US
Risk
46.6
Sharpe
1.25
Luna's Score
63/100
Recommendation
Hold
Luna says (ELDN | US)
What's Working
Positive Momentum
Strength based on increasing price with high volume
High Current Volume and Positive 1-Day Return
Low Debt to Equity (< 0.25)
Value Stock (Price to Book < 3)
Strong Sharpe Ratio (> 1.2)
What's not Working
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
49.4%1 month
46.6%3 months
54.5%6 months
69.7%Returns
Fundamental Ratios
PE
6.60
Fwd. PE
5.39
Price to book
1.31
Debt to equity
-0.08
Debt to assets
0.01
Ent. to EBITDA
0.84
Ent. to rev.
-
PEG
-
Other Fundamentals
EBITDA
-36.86M
MarketCap
125.39M
MarketCap(USD)
125.39M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-
Ret. on equity
-70.71
Short ratio
1.57
Short perc.
0.36
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Range10D
0.53
Range1M
0.71
Range3M
0.97
Volumes: Market Activity
Rel. volume
2.22
Price X volume
456.65K
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 0.84 | - | Expensive |
| Ent. to Revenue | - | - | - |
| PE Ratio | 6.60 | 41.03 | Cheaper |
| Price to Book | 1.31 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 54.48 | - | Lower Risk |
| Debt to Equity | -0.08 | -1.23 | Expensive |
| Debt to Assets | 0.01 | 0.25 | Cheaper |
| Market Cap | 125.39M | - | Emerging |
